Form 4: Artelo Biosciences Director Kelly Steven Amends Stock Option Holdings
SEC Form 4
Director Kelly Steven reports adjustments to stock option holdings in Artelo Biosciences, including repricing and revesting of certain options.
Summary
- On February 28, 2024, Kelly Steven, a director of Artelo Biosciences, filed a Form 4 detailing changes in their beneficial ownership of derivative securities.
- The changes involve adjustments to stock options, including repricing and revesting, as part of an offer approved by the Issuer's Compensation Committee.
- The adjustments reflect a 1-for-15 reverse stock split that occurred on August 10, 2022.
- Kelly Steven now holds various stock options with different exercise prices and expiration dates, some of which were acquired and others disposed of as part of the repricing and revesting offer.
- The total number of shares underlying these options is adjusted to reflect the reverse stock split.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine filing related to stock option adjustments, which doesn't inherently indicate positive or negative sentiment.
Positives
- The repricing and revesting offer suggests an effort to incentivize and retain key personnel.
- The director's continued service is tied to the vesting of the amended stock options, aligning their interests with the company's long-term success.
Industry Context
Stock option repricing and revesting are common practices in the biotech industry to retain talent, especially after events like reverse stock splits that can impact the value of existing options.
Comparison to Industry Standards
- Repricing stock options is a fairly common practice, especially in volatile sectors like biotechnology.
- Many companies, including those in the pharmaceutical and biotech industries, use similar strategies to maintain employee motivation and retention after significant stock price changes or corporate actions like reverse stock splits.
- Comparable companies might include other small-cap biotech firms that have undergone similar corporate restructuring and compensation adjustments.
Stakeholder Impact
- The repricing and revesting of stock options could potentially impact shareholder value, depending on the future performance of the company and the exercise of these options.
- Employees holding these options are directly impacted by the changes in vesting schedules and exercise prices.
Key Dates
| Date | Description |
|---|---|
| 02/12/2021 | Date of grant for stock options that were previously reported as covering 144,500 shares at an exercise price of $2.66 per share, but was adjusted to reflect a 1-for-15 reverse stock split that occurred on August 10, 2022. |
| 06/23/2022 | Date of grant for stock options that were previously reported as covering 10,000 shares at an exercise price of $1.00 per share, but was adjusted to reflect a 1-for-15 reverse stock split that occurred on August 10, 2022. |
| 06/24/2022 | Date of grant for stock options that were previously reported as covering 10,000 shares at an exercise price of $0.326 per share, but was adjusted to reflect a 1-for-15 reverse stock split that occurred on August 10, 2022. |
| 08/10/2022 | Date of 1-for-15 reverse stock split. |
| 02/12/2023 | Original exercisable date for stock options. |
| 06/24/2023 | Original exercisable date for stock options. |
| 06/30/2023 | Vesting Commencement Date for stock options. |
| 08/04/2023 | Vesting Commencement Date for stock options. |
| 02/28/2024 | Date of transaction and amendment of stock options. |
| 03/01/2024 | Date of signature for the Form 4 filing. |
Keywords
stock options, Form 4, Artelo Biosciences, director, Kelly Steven, repricing, revesting, derivative securities, beneficial ownership, reverse stock split
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.